½ÃÀ庸°í¼­
»óǰÄÚµå
1600594

¼¾Æ®·² ·¦ ½ÃÀå : ¼­ºñ½º À¯Çü, ´Ü°è, Ä¡·á ºÐ¾ß, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¾Æ®·² ·¦ ½ÃÀåÀº 2023³â¿¡ 31¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 33¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.25%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 57¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Áß¾Ó ½ÇÇè½Ç ½ÃÀåÀº Ç¥ÁØÈ­µÈ ½ÇÇè½Ç ¼­ºñ½º¸¦ Á¦°øÇÏ¿© ÀÓ»ó½ÃÇèÀ» Áö¿øÇÏ´Â ½ÇÇè½Ç ³×Æ®¿öÅ©·Î ±¸¼ºµÇ¸ç, ¼­·Î ´Ù¸¥ ½Ã¼³ °£¿¡ ÀϰüµÇ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °Ë»ç¸¦ º¸ÀåÇÕ´Ï´Ù. Á¦¾à»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)´Â µ¥ÀÌÅÍ Áß¾ÓÁýÁßÈ­, °Ë»ç ÀýÂ÷ÀÇ ÅëÀϼº, ³³±â ´ÜÃà µî ÀǾàǰ °³¹ß ÇÁ·Î¼¼½ºÀÇ ¼Óµµ¸¦ ³ôÀÌ´Â µ¥ ÇʼöÀûÀÎ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ½ÇÇè½ÇÀÇ Á߿伺ÀÌ ¸Å¿ì Å®´Ï´Ù. ÀÓ»ó½ÃÇèÀÇ º¹À⼺ ¹× ¼¼°èÈ­¿¡ µû¶ó ±ÔÁ¦ ±âÁØÀ» ¾ö°ÝÇÏ°Ô ÁؼöÇÏ°í µ¥ÀÌÅÍ °ü¸®¸¦ °­È­Çϱâ À§ÇØ Áß¾Ó ½ÇÇè½ÇÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â ¾à¹°´ë»ç½ÃÇè, ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®, µ¿¹ÝÁø´Ü, ƯÈ÷ Á¾¾çÇÐ ¹× ¸¸¼ºÁúȯ ÀÓ»ó½ÃÇè¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀº ½Å¾à °³¹ß ¼ö¿ä Áõ°¡, Áø´Ü °Ë»ç ±â¼úÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ Àúº¯ È®´ëÀÔ´Ï´Ù. ½ÅÈï ½ÃÀå ÁøÃâ°ú À¯ÀüüÇÐ ¹× ´Ü¹éÁúüÇÐÀÇ Áøº¸¸¦ Ȱ¿ëÇÏ¿© º¸´Ù Àü¹®ÀûÀÎ ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀÇ ¼ºÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ³ôÀº ¿î¿µ ºñ¿ë, ´Ù¾çÇÑ ÀÓ»ó½ÃÇè ±â°ü °£ÀÇ µ¥ÀÌÅÍ °ü¸® ¹× ÅëÇÕ°ú °ü·ÃµÈ ¹®Á¦ µîÀÇ ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. °æÀï ¿äÀÎÀ¸·Î´Â µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã °ü·Ã ÀáÀçÀû À§Çè°ú °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇÑ ±â¼ú ÀÎÇÁ¶óÀÇ Áö¼ÓÀûÀÎ ¾÷±×·¹À̵å Çʿ伺ÀÌ ÀÖ½À´Ï´Ù. Çõ½Å ºÐ¾ß·Î´Â µ¥ÀÌÅÍ ºÐ¼®, ÇÁ·Î¼¼½º ÀÚµ¿È­, ¿¹Ãø ºÐ¼®À» °­È­Çϱâ À§ÇÑ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ µµÀÔÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿øÈ°ÇÑ µ¥ÀÌÅÍ Àü¼ÛÀ» À§ÇÑ ÅëÇÕ Ç÷§Æû °³¹ß ¹× µ¥ÀÌÅÍ º¸¾ÈÀ» º¸ÀåÇϱâ À§ÇÑ ÇÏÀÌÅ×Å© ±â¾÷°úÀÇ Á¦ÈÞ´Â Å« ¼öÀÍÀ» âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. Áß¾Ó ½ÇÇè½Ç ½ÃÀåÀº Á÷¸éÇÑ °úÁ¦, Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä, ½ÇÇè½Ç ¼­ºñ½º¿¡ ÷´Ü ±â¼úÀ» ÅëÇÕÇÏ´Â °ÍÀ» ÁÖ¿ä ¿øµ¿·ÂÀ¸·Î »ï¾Æ ÀÌÇØ°ü°èÀÚµéÀÌ Çõ½Å°ú ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖ´Â ÁÁÀº ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 31¾ï 1,000¸¸ ´Þ·¯
ÃßÁ¤ ¿¬µµ(2024³â) 33¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 57¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 9.25%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¼¾Æ®·² ·¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¼¾Æ®·² ·¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÀÓ»ó½ÃÇè ¼ö Áõ°¡¿Í ÀǾàǰ °³¹ß Ȱµ¿ÀÇ º¹À⼺ Áõ°¡
    • ¼¼°è Á¤¹ÐÀÇ·á Ȱ¼ºÈ­¸¦ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼¾Æ®·² ·¦ ¼³¸³ ¹× À¯Áö¿¡ ¼Ò¿äµÇ´Â ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Áß¾Ó °Ë»ç½ÇÀÇ ±â¼ú ÅëÇÕ°ú ½º¸¶Æ® ±â´É
    • ¼¾Æ®·² ·¦ ¼³¸³ ¹× È®ÀåÀ» À§ÇÑ ÅõÀÚ
  • ½ÃÀå °úÁ¦
    • ¿î¿µ»óÀÇ ÇѰè¿Í Ç¥ÁØÈ­ÀÇ º¹À⼺

Portre's Five Forces: ¼¾Æ®·² ·¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼¾Æ®·² ·¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼¾Æ®·² ·¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¼¾Æ®·² ·¦ ½ÃÀå¿¡¼­ÀÇ °æÀï»óȲ ÆÄ¾Ç

¼¾Æ®·² ·¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º¼¾Æ®·² ·¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áß¾Ó ½ÇÇè½Ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¼¾Æ®·² ·¦ ½ÃÀå : ¼­ºñ½º À¯Çüº°

  • ÇØºÎ º´¸®ÇÐ/Á¶Á÷ÇÐ
  • ¹ÙÀÌ¿À¸¶Ä¿ ¼­ºñ½º
  • À¯ÀüÀÚ ¼­ºñ½º
  • ¹Ì»ý¹°ÇÐ ¼­ºñ½º
  • Ư¼öÈ­ÇÐ ¼­ºñ½º
  • Ç¥º» °ü¸® ¹× º¸°ü

Á¦7Àå ¼¾Æ®·² ·¦ ½ÃÀå : ´Ü°èº°

  • ´Ü°è 1
  • ´Ü°è 2
  • ´Ü°è 3

Á¦8Àå ¼¾Æ®·² ·¦ ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • ÀÚ°¡¸é¿ªÁúȯ
  • ½ÉÇ÷°üÁúȯ
  • °¨¿°Áõ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ

Á¦9Àå ¼¾Æ®·² ·¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • Çмú¿¬±¸±â°ü
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • º´¸®ÇÐ ¹× Áø´Ü½ÇÇè½Ç
  • Á¦¾àȸ»ç

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼¾Æ®·² ·¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼¾Æ®·² ·¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼¾Æ®·² ·¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • ACM Medical Laboratory, Inc.
  • Almac Group
  • Cerba HealthCare
  • CROMSOURCE by ClinChoice
  • Cryoport, Inc.
  • Eurofins Scientific SE
  • Exagen Inc.
  • Frontage Laboratories, Inc.
  • GBA Group
  • GCCL Co., Ltd.
  • ICON PLC
  • InterlabCorp
  • Intertek Group PLC
  • IQVIA Inc.
  • LabConnect, Inc.
  • Laboratory Corporation of America Holdings
  • Lambda Therapeutic Research Ltd.
  • Lotus Labs Pvt. Ltd. by Teva Pharmaceutical Industries Ltd.
  • MDS Pharma Services
  • Medicover AB
  • Medpace, Inc.
  • MLM Medical Labs GmbH
  • Novotech Health Holdings
  • Pace Analytical Services, LLC
  • Precision Medicine Group, LLC
  • Quest Diagnostics Incorporated
  • REPROCELL Inc.
  • SGS S.A.
  • Shanghai Clinical Research Center
  • SMS Pharmaceuticals Ltd.
  • Sonic Healthcare International
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Unilabs AB
  • Versiti, Inc.
  • WuXi AppTec
LSH

The Central Lab Market was valued at USD 3.11 billion in 2023, expected to reach USD 3.38 billion in 2024, and is projected to grow at a CAGR of 9.25%, to USD 5.78 billion by 2030.

The Central Lab market comprises a network of laboratories that support clinical trials by providing standardized laboratory services, ensuring consistent and reliable testing across different sites. These labs are crucial for pharmaceutical companies, biotech firms, and contract research organizations (CROs) as they offer centralization of data, uniformity in testing procedures, and reduction in turnaround times-vital for speeding up drug development processes. The necessity for central labs has grown with the increasing complexity and globalization of clinical trials, requiring strict adherence to regulatory standards and facilitating enhanced data management. Applications mainly encompass drug metabolism studies, biomarker analyses, and companion diagnostics, especially in oncology and chronic disease trials. The market's growth is driven by heightened demand for new drug development, technological advancements in diagnostic testing, and a broader scope for personalized medicine. Opportunities lie in the expansion into emerging markets and leveraging advancements in genomics and proteomics to offer more specialized services. However, market growth faces limitations in the form of stringent regulatory frameworks, high operational costs, and challenges associated with data management and integration across various trial sites. Adverse factors include potential risks related to data privacy and the need for constantly upgrading technological infrastructure to stay competitive. Innovative areas to explore include the incorporation of artificial intelligence and machine learning to enhance data analysis, process automation, and predictive analytics. Moreover, developing integrated platforms for seamless data transfer and partnering with tech companies to ensure secure data handling could offer significant returns. The Central Lab market, while facing challenges, presents robust opportunities for stakeholders to innovate and grow, largely driven by the continuous demand for innovative therapeutic solutions and the integration of cutting-edge technologies into laboratory services.

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.38 billion
Forecast Year [2030] USD 5.78 billion
CAGR (%) 9.25%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Lab Market

The Central Lab Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the number of clinical trials and complexity of drug development activities
    • Government initiatives promoting precision medicine worldwide
  • Market Restraints
    • High cost of set-up and maintenance of central labs
  • Market Opportunities
    • Technological integrations and smart features in central labs
    • Investments for establishment and expansion of central labs
  • Market Challenges
    • Operational limitations and standardization complexities

Porter's Five Forces: A Strategic Tool for Navigating the Central Lab Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Lab Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Lab Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Lab Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Lab Market

A detailed market share analysis in the Central Lab Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Lab Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Lab Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Central Lab Market, highlighting leading vendors and their innovative profiles. These include ACM Medical Laboratory, Inc., Almac Group, Cerba HealthCare, CROMSOURCE by ClinChoice, Cryoport, Inc., Eurofins Scientific SE, Exagen Inc., Frontage Laboratories, Inc., GBA Group, GCCL Co., Ltd., ICON PLC, InterlabCorp, Intertek Group PLC, IQVIA Inc., LabConnect, Inc., Laboratory Corporation of America Holdings, Lambda Therapeutic Research Ltd., Lotus Labs Pvt. Ltd. by Teva Pharmaceutical Industries Ltd., MDS Pharma Services, Medicover AB, Medpace, Inc., MLM Medical Labs GmbH, Novotech Health Holdings, Pace Analytical Services, LLC, Precision Medicine Group, LLC, Quest Diagnostics Incorporated, REPROCELL Inc., SGS S.A., Shanghai Clinical Research Center, SMS Pharmaceuticals Ltd., Sonic Healthcare International, Syngene International Limited, Thermo Fisher Scientific Inc., Unilabs AB, Versiti, Inc., and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Central Lab Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Service Type, market is studied across Anatomic Pathology/Histology, Biomarker Services, Genetic Services, Microbiology Services, Special Chemistry Services, and Specimen Management & Storage.
  • Based on Phase, market is studied across Phase 1, Phase 2, and Phase 3.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, and Oncology.
  • Based on End-use, market is studied across Academic & Research Institutes, Biotechnology Companies, Pathology & Diagnostic Lab, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the number of clinical trials and complexity of drug development activities
      • 5.1.1.2. Government initiatives promoting precision medicine worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of set-up and maintenance of central labs
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological integrations and smart features in central labs
      • 5.1.3.2. Investments for establishment and expansion of central labs
    • 5.1.4. Challenges
      • 5.1.4.1. Operational limitations and standardization complexities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Services Type: Preference for central labs for long-term storage of biological samples under controlled conditions for specific management
    • 5.2.2. Phase: Integral role of the central labs for the execution of the entire clinical trial process
    • 5.2.3. End-use: Need to facilitate seamless clinical trials, ensuring data integrity and operational excellence for pharmaceutical companies
    • 5.2.4. Therapeutic Area: Comprehensive diagnostic and prognostic testing for oncology and infectious diseases therapeutic areas
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Lab Market, by Service Type

  • 6.1. Introduction
  • 6.2. Anatomic Pathology/Histology
  • 6.3. Biomarker Services
  • 6.4. Genetic Services
  • 6.5. Microbiology Services
  • 6.6. Special Chemistry Services
  • 6.7. Specimen Management & Storage

7. Central Lab Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase 1
  • 7.3. Phase 2
  • 7.4. Phase 3

8. Central Lab Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cardiovascular Diseases
  • 8.4. Infectious Diseases
  • 8.5. Neurology
  • 8.6. Oncology

9. Central Lab Market, by End-use

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology Companies
  • 9.4. Pathology & Diagnostic Lab
  • 9.5. Pharmaceutical Companies

10. Americas Central Lab Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Lab Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Lab Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Medpace Central Labs Expand Singapore Facility
    • 13.3.2. Vial Announces Collaborative Alliance with MLM Medical Labs for offering Central Laboratory Solutions
    • 13.3.3. Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
    • 13.3.4. Cleveland Clinic and LabConnect announce Strategic Alliance for Improved Patient Care
    • 13.3.5. Versiti Acquires Indiana-based Quantigen for Accelerating Pace of Innovation for Preclinical Research Services
    • 13.3.6. Labor Dr. Wisplinghoff and Labconnect Announce Strategic Alliance - Expanding Global Central Laboratory Services to Accelerate the Development of Medicines
    • 13.3.7. IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
    • 13.3.8. Cerba Research Offers a Customized, Innovative Approach to its Partners in the Laboratory Services
    • 13.3.9. Medpace Central Labs Expand Histology & Anatomic Pathology Services
    • 13.3.10. Thermo Fisher to invest USD 59 Million for Clinical Research Lab Expansion in the U.S.

Companies Mentioned

  • 1. ACM Medical Laboratory, Inc.
  • 2. Almac Group
  • 3. Cerba HealthCare
  • 4. CROMSOURCE by ClinChoice
  • 5. Cryoport, Inc.
  • 6. Eurofins Scientific SE
  • 7. Exagen Inc.
  • 8. Frontage Laboratories, Inc.
  • 9. GBA Group
  • 10. GCCL Co., Ltd.
  • 11. ICON PLC
  • 12. InterlabCorp
  • 13. Intertek Group PLC
  • 14. IQVIA Inc.
  • 15. LabConnect, Inc.
  • 16. Laboratory Corporation of America Holdings
  • 17. Lambda Therapeutic Research Ltd.
  • 18. Lotus Labs Pvt. Ltd. by Teva Pharmaceutical Industries Ltd.
  • 19. MDS Pharma Services
  • 20. Medicover AB
  • 21. Medpace, Inc.
  • 22. MLM Medical Labs GmbH
  • 23. Novotech Health Holdings
  • 24. Pace Analytical Services, LLC
  • 25. Precision Medicine Group, LLC
  • 26. Quest Diagnostics Incorporated
  • 27. REPROCELL Inc.
  • 28. SGS S.A.
  • 29. Shanghai Clinical Research Center
  • 30. SMS Pharmaceuticals Ltd.
  • 31. Sonic Healthcare International
  • 32. Syngene International Limited
  • 33. Thermo Fisher Scientific Inc.
  • 34. Unilabs AB
  • 35. Versiti, Inc.
  • 36. WuXi AppTec
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦